China’s GLP-1 Market Enters a New Era of Competition and Access
China’s GLP-1 market is poised for another major shift as Pfizer’s ecnoglutide and Innovent Biologics’ mazdutide move closer to national medical insurance inclusion. Reimbursement could lower treatment costs and expand patient access, while intensifying competition among global and domestic drugmakers. With price negotiations ahead, China’s evolving GLP-1 landscape could reshape market share, pricing and demand.